CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.
Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T细胞适应性已成为嵌合抗原受体(CAR)-T细胞疗法疗效与持久性的关键决定因素。T细胞适应性由T细胞增殖、抵抗耗竭、体内持久存在以及发挥持续效应功能的能力所定义,反映了内在与外在调控机制动态网络的整合。在本综述中,我们全面综合了T细胞适应性背后的分子与细胞基础,强调分化轨迹、信号通路、代谢重编程和表观遗传修饰的影响。
我们进一步讨论了患者特异性条件(如年龄)以及疾病生物学、既往治疗暴露、T细胞采集时机与质量对CAR-T 细胞产品表型与功能疗效的影响。除了描述这些决定因素外,我们还重点介绍了旨在增强T细胞适应性的新兴策略。
重要的是,我们提出T细胞适应性是一种整合的、多层级的系统属性,源于分化状态、信号架构、代谢-线粒体能力、表观遗传稳定性以及宿主特异性炎症和治疗相关压力之间的相互作用。
我们引入了一个机制框架,将CAR-T 治疗时间线从白细胞分离术到输注后肿瘤交战中的这些层面联系起来,并概述了该框架如何可操作化为可测量参数,以指导患者分层、生产决策和合理的治疗干预。
T cell fitness has emerged as a critical determinant of the efficacy and persistence of Chimeric Antigen Receptor (CAR)-T cell therapy. Defined by the capacity of T cells to proliferate, resist exhaustion, persist in vivo , and exert sustained effector functions, T cell fitness reflects the integration of a dynamic network of intrinsic and extrinsic regulatory mechanisms.
In this review, we present a comprehensive synthesis of the molecular and cellular foundations underlying T cell fitness, emphasizing the influence of differentiation trajectories, signaling pathways, metabolic reprogramming, and epigenetic modifications.
We further discuss the impact of patient-specific conditions such as age as well as disease biology, prior therapeutic exposures, and timing and quality of T cell collection, on the phenotypic and functional efficacy of CAR-T cell products. Beyond delineating these determinants, we highlight emerging strategies aimed at enhancing T cell fitness.
Importantly, we propose T cell fitness as an integrated, multi-layered systems property emerging from the interaction between differentiation state, signaling architecture, metabolic-mitochondrial competence, epigenetic stability, and host-specific inflammatory and treatment-related pressures.
We introduce a mechanistic framework that links these layers across the CAR-T therapeutic timeline from leukapheresis to post-infusion tumor engagement and outline how this framework can be operationalized into measurable parameters to guide patient stratification, manufacturing decisions, and rational therapeutic interventions.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。